Investors eye Anlon Healthcare IPO launch on August 26 with 121 crore fresh issue (Freepik)
Anlon Healthcare Ltd, which is based at Rajkot, is one of the pharmaceutical companies set to enter the capital market with its first ever initial public offering or IPO on 26 August. This issuance is pegged at ₹121.03 crore and consists entirely of a fresh issue of 1.33 crore equity shares. Established in 2013, the organization has begun its production operations since 2017 and has garnered expertise in active pharmaceutical ingredients (APIs), intermediates and nutraceutical products.
The price band for the IPO has been fixed between ₹86 and ₹91 per share. Of the total issue size, 75% is reserved for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and the remaining 10% for participants interested in retail offerings. These retail investors can participate through bidding in blocks of at least one lot consisting of 164 shares or a minimum investment amount of ₹14,924.
ALSO READ: New Nifty Entries to Get Massive Inflows; Here are the Details
The minimum investment limits are way higher for high-net-worth investors. For instance, small HNIs will have to apply for a minimum of 14 lots (2296 shares) requiring investment of ₹2.08 lakh, while for large HNIs, the starting point is 68 lots (11152 shares) which require commitment of over ₹10 lakh. Interactive Financial Services Ltd is going to be the lead manager to the issue, while Technologies Ltd will take over as registrar.
The subscription window for IPO will be kept open between August 26 and August 29. Allotment of shares is expected to be done around September 1, followed by refunds and credits to demat accounts for September 2.
ALSO READ: Nifty50 Re-shuffle: BSE Isn’t Getting Entry, These Stocks Get the Nod
If things go along the prescribed lines, the stock of Anlon Healthcare will be available for trading on both the NSE and BSE on September 3. No visible gray market premium (GMP) has surfaced at the moment, but things may pick up as the opening date draws closer.
Performance-wise, Anlon Healthcare has grown remarkably into one of the few Indian companies to achieve almost 80% increase in revenue from ₹66.69 crore during FY24 to ₹120.46 crore in FY25. More than double the company's revenue in net profit terms rose from ₹9.66 crore to ₹20.52 crore during the same period.
An amount from the IPO will go into new capital expenditure, repayments of secured borrowings, and working capital needs against general corporate purposes. This will further enhance its balance sheet weightage in support of its next phase of expansion.
An opportunity for investors keen on the long-term potential of the pharmaceutical sector with the firm's consistent financial growth along with the judicious use of the fresh capital drawn from the IPO represents Anlon Pharmaceuticals for the benefit of investment.
ALSO READ: Gold Promises to be the Safe Haven amid the Uncertain Turmoils Around
